Kornimate/medical-research-clean huggingface dataset:
study of blood flow in heart muscle

Conditions: Coronary Disease; Healthy; Hypertrophic Cardiomyopathy; Myocardial Ischemia

Summary: blood flows to areas of the heart providing oxygen and fuel to the pumping muscle. occasionally the arteries providing the fuel can become blocked. this occurs in coronary artery disease. magnetic resonance imaging (mri) can be used to evaluate the blood flow to different areas of the heart muscle. in this study magnetic resonance imaging will be compared to other diagnostic tests (radionucleotide perfusion studies) capable of measuring blood flow to heart muscle.

in this pilot study, magnetic resonance imaging (mri) of myocardial enhancement during first passage of intravenously injected gadolinium contrast will be used to evaluate regional myocardial perfusion in patients with known or suspected coronary artery disease and hypertrophic cardiomyopathy. the mri results will be compared with conventional radionuclide perfusion studies (ex. dipyridamole thallium). a clinically defined normal group will also be studied without radionuclide correlation.

Eligibility criteria:
inclusion criteria: ages 18 to 80. either sex. capable of giving informed consent. group 1: outpatients with known or suspected coronary artery disease with clinical indication for radionuclide perfusion imaging. group 2: patients with non-obstructive hypertrophic cardiomyopathy with clinical indication for radionuclide perfusion imaging. group 3: normal volunteers. positive stress thallium or stress sestamibi (i.e., exercise, adenosine, dobutamine or dypiridamole) at the nih. exclusion criteria: pregnancy. unstable angina. uncontrolled hypertension (sbp greater than 185, dbp greater than 105). recent myocardial infarction (less than 5 days). 2nd or 3rd degree heart block by ecg. asthma, emphysema, renal failure, acute medical illness (fever, pneumonia, etc.) or anemia (hct less than 30). cardiac pacemaker or implantable defibrillator, aneurysm clip, neural stimulator, any type of ear implant, metal in your eye, any implanted device (i.e. insulin pump, drug infusion device) or any metallic foreign body, shrapnel, or bullet.

Keywords: gadolinium ischemia coronary artery disease hypertrophic cardiomyopathy dipyridamole
recruitment maneuver after bronchoalveolar lavage in ards patients

Conditions: Acute Respiratory Distress Syndrome

Summary: ards caused by pneumonia is one of the main reasons for icu admission in critically ill patients, and also a common complication in patients admitted to icu with invasive mechanical ventilation. bronchoalveolar lavage (bal) is the main diagnostic method for these patients, which often leads to alveolar collapse and exacerbates hypoxemia. in clinical practice, recruitment maneuver (rm) is often used immediately after bal to prevent such a situation, but there is a lack of data on rm after bal.


Eligibility criteria:
inclusion criteria: 1. adult patients with invasive mechanical ventilation; 2. patients who diagnosed with ards according to the berlin definition 3. there are indications for bronchoalveolar lavage exclusion criteria: 1. patients with contraindications for eit procedures; 2. patients with contraindications for rm; 3. previous chronic respiratory diseases (long-term home oxygen therapy for chronic respiratory diseases such as pulmonary fibrosis or copd); 4. pregnancy; 5. refusal to sign informed consent
recombinant versus highly purified fsh in polycystic ovary syndrome (pcos)

Conditions: Polycystic Ovary Syndrome

Summary: control ovarian stimulation responses, pregnancy and miscarriage rates are indifferent when either recombinant or highly purified follicle stimulating hormone (fsh) is used.

patients will be randomized using sealed and numbered envelopes and will be assigned to receive a similar ovarian stimulation regime incorporating either gonal-f or highly purified fostimon as the hormonal analog. ovarian response using either of the two compounds, pregnancy rates and miscarriage rates will be compared to define possible statistical significance.

Eligibility criteria:
inclusion criteria: * pcos * primary infertility * no other fertility manifestation exclusion criteria: * non pcos * secondary infertility

Keywords: ovarian response in pcos pregnancy rate in pcos miscarriage rate in pcos
students, parents, and teachers on track: intervention development for youth with emotional disturbance

Conditions: Emotional Disturbance

Summary: the purpose of the on track intervention is to address a need raised by a day-treatment school in lane county: support for students transitioning from the day-treatment school (lane school) to their district middle schools. eligible students are currently attending lane school, in middle school (grades 6-8), with or at risk for emotional disturbance, and are preparing to transition to their district schools.

a significant problem in education is that the transition period between a treatment school and a district school represents a high-risk time for failure. education service district and school district leadership in lane county contacted the oregon social learning center to collaborate on this project stating that during this transition period the students have insufficient strategies, services, and supports for generalizing the gains made at lane school (the treatment school) back into the district middle school setting. they reported that this is a period of high stress and instability for many students and their families. additionally, district schools lack the resources and supports to import the strategies that supported students to be successful at lane school. lane school works to track students' placement and services following completion of their program and data indicate that in the first year after transition, approximately 82% of middle school students transfer to public schools in their home district and the remaining students transfer directly to alternative or in-patient treatment centers. by the second year after transition, however, the majority of students who attended public schools were placed in self-contained classrooms, alternative placements, treatment centers, or received out-of-school tutoring due to emotional and behavioral problems. in addition, many students have high rates of truancy and low levels of parental support. this project is intended to address the gaps in support to increase placement stability at the district schools following the transition. to date, four students have begun the transition process with support from this project. one student has fully transitioned and results from qualitative interviews with the parent and the teacher indicate that the intervention is well liked and providing the supports needed to promote student success at the district middle school. we will continue to collect data to determine the level impact in this domain. a secondary impact is developing strategies to effectively collaborate with multiple school districts to support the common goal of transitioning students smoothly and sustaining placement stability. it is our goal to disseminate these strategies via publications and presentations with other educational researchers and practitioners.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of emotional and behavioral disturbance

Keywords: emotional disturbance behavioral disturbance ebd middle school special education school psychology
phase 2 study of sbrt plus tislelizumab and regorafenib in unresectable or oligometastatic hcc

Conditions: Unresectable Hepatocellular Carcinoma; Oligometastatic Disease

Summary: the goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (sbrt) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic hepatocellular carcinoma (hcc). the main question to answer is: whether combing sbrt with immunotherapy and targeted therapy could prolong pfs. participants will receive sbrt to all visible lesions and concurrent systemic immunotherapy and targeted therapy.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * eastern cooperative oncology group performance status of 0-1 * clinical or pathological diagnosis of hcc * with unresectable locally advanced or oligometastatic hcc (metastatic lesions ≤ 5, metastatic organs ≤ 3, may involve extrahepatic lymph nodes or distant organs apart from brain) * at least one measurable lesion according to mrecist criteria * all lesions could be included in radiation target volume * child-pugh a or b (7 scores) liver function * patients are allowed to receive systemic therapy previously other than tislelizumab plus regorafenib * adequate hematological and renal function * life expectancy ≥ 3 months； * willing to participate in the study and give written informed consent exclusion criteria: * a history of liver transplantation * with severe cirrhosis complications, including a history of esophagogastric variceal bleeding, hepatic encephalopathy, and massive ascites * with active autoimmune diseases or a history of autoimmune disease * with human immunodeficiency virus (hiv) infection or acquired immunodeficiency syndrome (aids) * allergic to the ingredient of tislelizumab or regorafenib * with recurrent lesions treated with radiotherapy previously * prescribed radiation does could not be delivered due to dose limits to organs at risk (oar) * intolerable to radiation or systemic treatment because of cardiac insufficiency, uncontrolled high blood pressure * a history of other malignancies, except cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
building engagement using financial incentives trial - colorectal cancer screening

Conditions: Health Behavior; Colorectal Cancer; Influenza; COVID-19; Vaccine Hesitancy; Vaccine-Preventable Diseases; Healthcare Patient Acceptance

Summary: the goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. the main questions it aims to answer are: * do patient financial incentives for completing colorectal cancer screening increase screening completion? * does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for covid-19 and flu shots increase completion of those shots? participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. participants will be randomly assigned to either group 1 or group 2. group 1 participants will be offered financial incentives for completing covid-19 and flu shots within 2 months of enrollment. group 2 participants will be offered financial incentives for completing a covid-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment. researchers will compare to see if completion of a covid-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.


Eligibility criteria:
inclusion criteria: * age 45 to 75 * receive care at participating primary care clinic * due for colorectal cancer screening * ability to understand and speak english exclusion criteria: * currently participating in another clinical trial or research study on colorectal cancer screening * unable or unwilling to give informed consent

Keywords: cancer screening preventive healthcare vaccine uptake patient financial incentives federally qualified health center health services
study of leuprolide acetate injectable suspension in the treatment of central precocious puberty

Conditions: Precocious Puberty, Central

Summary: this study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with central precocious puberty.

leuprolide acetate is a gnrh agonist that inhibits pituitary gonadotropin secretion by binding to the gnrh receptors and blocking downstream hormone synthesis. the steady decrease in hormone synthesis (lh and fsh) leads to a suppression of testicular and ovarian steroidogenesis. in children with cpp, this steady decrease in hormone synthesis disrupts the progression of puberty.

Eligibility criteria:
inclusion criteria: * females age 2 to 8 years (inclusive) or males age 2 to 9 years (inclusive) * confirmed diagnosis of cpp within 12 months of baseline visit (day 0) but have not received prior gnrh agonist treatment for cpp * pubertal-type lh response following an abbreviated gnrha stimulation test before treatment initiation * clinical evidence of puberty, defined as tanner stage ≥ 2 for breast development in females or testicular volume ≥ 4 ml in males * difference between bone age (greulich and pyle method) and chronological age ≥ 1 year exclusion criteria: * gonadotropin-independent (peripheral) precocious puberty * prior or current gnrh treatment for cpp * prior or current therapy with medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (igf-1) * diagnosis of short stature (ie, 2.25 standard deviations (sd) below the mean height for age) * known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions * any other medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the subject to participate in the study
clinical and radiographic evaluation of revascularization of immature anterior permanent teeth using concentrated growth factor (cgf) versus blood clot (bc)

Conditions: Revascularization

Summary: the aim of this study is to compare clinical and radiographic evaluation treatment of necrotic immature permanent teeth using: 1. concentrated growth factor 2. blood clot

rationale for conducting the research: concentrated growth factor (cgf) is relatively a new generation of platelet concentrate product, it contains more cytokines and growth factors compared with prp and prf also promotes the proliferation, migration, and differentiation of stem cells.

Eligibility criteria:
inclusion criteria: 1. children aged between 8_14 years. 2. anterior tooth diagnosed with necrotic pulp (due to trauma, caries, or anomaly) responded negatively to sensibility tests. 3. teeth not indicated for post and core. 4. a cooperative and compliant patient/parent. 5. patients not allergic to medicaments necessary to complete the procedure. 6. patients with no history of chronic systemic diseases. exclusion criteria: 1. medically compromised patient. 2. teeth with vertical fractures. 3. non-restorable teeth. 4. teeth when bleeding could not be induced. 5. unable to attend follow-up visits.
most: mediterranean oncology senior tests

Conditions: Colon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting; Aged 70 or Older

Summary: most is a longitudinal study whose aim is to test the hypothesis that frailty markers are better at detecting vulnerable patients and that they are a better "adverse events" predictive tool than the cga (comprehensive geriatric assessment) in older cancer patients referred for chemotherapy. the second hypothesis is that a brief screening tool based on a combination of some frailty markers and some used in the cga would help the oncologist detect patients requiring a more complete geriatric assessment

for older cancer patients, comprehensive geriatric assessment (cga) is recommended in order to help the oncologist in his decision making. however, the implementation of the cga in oncologic setting presents major limitations; the cga is time consuming, costly in terms of resources and is not standardized. moreover, recent studies show that the cga, used as the gold standard, may have a ceiling effect in detecting vulnerability in older cancer patients. several authors suggest that a more sensitive approach, using frailty markers may be a better way to detect potential vulnerability in older cancer patients. in this study, for each patient, a brief screening assessment, a full cga and the assessment of frailty markers will be completed at inclusion. the brief screening assessment will be based on self report questionnaire (4 items of instrumental activities of daily living + 2 items of nutritional assessment) and one physical measure (one-leg standing balance test). the cga will be based on seven domains (and their assessment tools): functional status, comorbidities, objective physical performance, nutrition, cognition, depression, and social support. five frailty markers (as described by fried and al) will be evaluated: nutrition, mobility, energy, physical activity and grip strength. cga and frailty markers will be completed at 3, 6, 12 and 18 months after the beginning of chemotherapy as well as oncologic criteria (treatment toxicities, treatment modification such as decrease or change or end of chemotherapy, percentage of chemotherapy dose received, cancer related death) and geriatric criteria for adverse outcomes (functional, nutritional or cognition decline, hospitalization or consultation with their general practitioner, death for other causes).

Eligibility criteria:
inclusion criteria: * patients with colon cancer with or without metastases * age ≥ 70 years * patients did not start chemotherapy yet exclusion criteria: * patients terminally ill with a life expectancy \<3 months * patients who have started chemotherapy or hormonal therapy

Keywords: colon cancer elderly patients
prevalence of myocarditis in patients suspected myocardial infarction with non-obstructive coronary arteries

Conditions: Prevalence of Myocarditis in MINOCA Patients

Summary: this study aims to determine the prevalence of myocarditis among patients suspected of having myocardial infarction with non-obstructive coronary arteries (minoca) and to analyze its clinical characteristics, diagnostic markers .

acute myocardial infarction (ami) remains the leading causes of high morbidity and mortality worldwide, recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (minoca) has been increasingly recognized because of the widespread use of coronary angiography. minoca occurs in 5%-10% of all ami and they are younger and more often women compared to patients with ami and obstructive coronary artery disease (cad) , the underlying causes of minoca are manifold and may include plaque rupture or erosion, thromboembolism, coronary spasm, spontaneous dissection, microvascular dysfunction and supply/demand mismatch. some non-ischemic diseases such as myocarditis may also mimic the presentation of minoca .of note, several studies have found that the prognosis of minoca is not trivial and patients are still at considerable risks for long-term adverse cardiovascular (cv) events despite the optimal secondary prevention treatments \[\[6\], \[7\], \[8\], \[9\], \[10\]\]. thus, it is of necessity and profound implications to find potential residual risk factors and improve prognosis in minoca population. myocarditis is commonly caused by viral infections, but it can also be caused by bacterial infections, toxic substances, or autoimmune disorders . myocarditis is more common in younger patients, although it affects patients of all ages. fulminant myocarditis, although rare, can result in life-threatening cardiogenic shock . diagnosis of myocarditis is made using cmri characterized by the presence of diffuse myocardial edema on t2 and with myocardial biopsy . in a meta-analysis of five observational studies with available cmri data, one-third of minoca patients had myocarditis. it was more common in younger patients and those with high c-reactive protein .

Eligibility criteria:
inclusion criteria: * all patients; diagnosed with myocardial infarction with nonobstructive coronary arteries (minoca) * clinical symptoms * ecg : ischemic changes with or without st segment elevation * echocardiograpy : segmental wall motion abnormalities (swma) * positive cardiac enzymes * coronary angiography: insignificant lesions ,the absence of culprit obstructive coronary artery disease (epicardial coronary artery stenosis ≥50%) exclusion criteria: * significant coronary artery disease (\>50% stenosis) on angiography. * prior history of myocarditis or cardiomyopathy. * contraindications to cmr (e.g., pacemakers, severe renal dysfunction).

Keywords: myocarditis minoca normal coronary angiography
nano-pulse stimulation (nps) in seborrheic keratosis study

Conditions: Lesion Skin; Seborrheic Keratosis

Summary: the primary purpose of this trial is to evaluate nano-pulse stimulation (nps) to clear or remove seborrheic keratosis (sk) lesions from off-facial areas of healthy adult subjects.

evaluate nano-pulse stimulation (nps) to clear or remove seborrheic keratosis (sk) lesions from off-facial areas of healthy adult subjects. the specific objectives of this study are to: * document the non-treated appearance of off-face sks. * evaluate the clearance of sks in off-face locations post-treatment versus pre-treated appearance of the same lesion. * evaluate the clearance of the treated sks at various points in time over several weeks following the initial procedure, compared to the pre-treated sks.

Eligibility criteria:
inclusion criteria: * willing to sign the informed consent * has a clinical diagnosis of stable, clinically typical seborrheic keratosis * medically determined candidate for at least 4 off-face sk lesions * must have at least four treatable sk lesions and be willing to have nps treatment on any three of the four treatable sk lesions. treatable sk lesions must: be at least 1 mm in height, and no greater than 3 mm in height and not have a dimension perpendicular to the longest dimension of greater than 7.5mm or longer in any dimension than 20mm * willing to have three of the designated sk lesions treated in a single treatment session * willing to return to the pi's office for five additional study visits at specified intervals over 106-days * agrees to high resolution photos of both the treated sk lesions and the untreated sk lesion * no subject identity will be possible via the "lesion-only" photograph * no evidence of active infection in the designated tissue prior to treatment * is not allergic to lidocaine or lidocaine-like products * not pregnant or lactating exclusion criteria: * has an implantable electronic device (e.g., automatic defibrillator) * active infection or history of infection within 90 previous days in designated test area * not willing or able to sign the informed consent * non-english speaking or reading * is known to be immune-compromised * known to be a keloid producer * on blood thinning medications * diseases, conditions, or situations wherein the pi judges that the patient is not appropriate for participation in the study

Keywords: nano-pulse stimulation seborrheic keratosis
use of mobile phones for thermal imaging of the chest to save lives of children with pneumonia in nagpur, india

Conditions: Infections - Bacterial; Pneumonia - Bacterial

Summary: the purpose of this study is to see if thermal images can be used instead of a chest x-ray to diagnose bacterial pneumonia in children with signs and symptoms of pneumonia in nagpur, india. more specifically, the objectives of the study are: 1) to determine if thermal imaging, using a commercial thermal camera can accurately detect the presence of bacterial pneumonia in children receiving a chest x-ray to rule out pneumonia; 2) to evaluate the use of thermal imaging to monitor the course and resolution of pneumonia in children diagnosed with pneumonia; and 3) to determine if thermal imaging can accurately diagnose sites of infection that are suspected to be related to the pneumonia.


Eligibility criteria:
inclusion criteria: * 18 years or younger * patient at daga memorial hospital, nagpur, india * had chest x-ray within last 24 hours * consent obtained from one parent * assent obtained if child is 8 years or older exclusion criteria: * thermal image cannot be done within 24 hours of chest x-ray

Keywords: imaging diagnostic pediatrics